Suboxone, a medication used to treat opioid addiction, contains two active ingredients: buprenorphine and naloxone. Standard drug screenings do not typically detect buprenorphine unless the test is specifically designed to do so. The presence of naloxone is even less frequently screened for in routine drug tests.
The need to identify buprenorphine is crucial in various clinical settings, including monitoring patient compliance in addiction treatment programs and ensuring appropriate medication management. Historically, the detection of opioids focused primarily on substances like heroin, morphine, and codeine. However, the increasing use of medications like buprenorphine has necessitated the development of specialized assays.